Congratulations to our partners at Apogee Therapeutics for a milestone-filled year – from trading as a public company on Nasdaq to moving multiple programs into the clinic and advancing their mission of improving treatment for millions of people living with inflammatory and immune conditions. What a journey it has been witnessing the growth of our first spinout over the past year. Here's to much more continued success!
One year ago, Apogee began trading as a public company on Nasdaq! We have made significant strides since then, moving multiple programs forward in the clinic and getting closer to impacting millions of patients in need. We look forward to what's ahead and never stopping at "good enough."